Mawer Investment Management Ltd. Purchases 24,761 Shares of Becton, Dickinson and Company (BDX)

Mawer Investment Management Ltd. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,799,828 shares of the medical instruments supplier’s stock after acquiring an additional 24,761 shares during the quarter. Becton, Dickinson and accounts for approximately 3.0% of Mawer Investment Management Ltd.’s investment portfolio, making the stock its 5th biggest holding. Mawer Investment Management Ltd. owned approximately 0.79% of Becton, Dickinson and worth $352,599,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. SPF Beheer BV boosted its stake in shares of Becton, Dickinson and by 6.5% during the 3rd quarter. SPF Beheer BV now owns 388,447 shares of the medical instruments supplier’s stock worth $76,116,000 after acquiring an additional 23,559 shares in the last quarter. Harbour Capital Advisors LLC purchased a new stake in shares of Becton, Dickinson and during the 3rd quarter worth about $271,000. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of Becton, Dickinson and by 1.3% during the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 23,129 shares of the medical instruments supplier’s stock worth $4,532,000 after acquiring an additional 300 shares in the last quarter. Findlay Park Partners LLP boosted its stake in shares of Becton, Dickinson and by 2.3% during the 3rd quarter. Findlay Park Partners LLP now owns 1,765,000 shares of the medical instruments supplier’s stock worth $345,852,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Willingdon Wealth Management boosted its stake in shares of Becton, Dickinson and by 3.8% during the 3rd quarter. Willingdon Wealth Management now owns 15,890 shares of the medical instruments supplier’s stock worth $3,114,000 after acquiring an additional 584 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company (BDX) traded up $1.19 during mid-day trading on Tuesday, reaching $221.50. 807,900 shares of the company’s stock were exchanged, compared to its average volume of 1,322,965. The firm has a market cap of $50,130.00, a P/E ratio of 23.22, a price-to-earnings-growth ratio of 1.73 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $225.23.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. Becton, Dickinson and’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.12 EPS. analysts anticipate that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a $0.75 dividend. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 1.35%. Becton, Dickinson and’s dividend payout ratio is presently 62.80%.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/21/mawer-investment-management-ltd-purchases-24761-shares-of-becton-dickinson-and-company-bdx.html.

In other news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stephen Sichak sold 11,787 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the sale, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

A number of brokerages recently weighed in on BDX. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research note on Friday, October 20th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $214.79.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply